The WHI ten year's later: an epidemiologist's view.
Level 5 - mechanism / opinion, no new human data
Narrative review and expert commentary without systematic search or new data
PubMed 24029430 · doi:10.1016/j.jsbmb.2013.08.006
What was done
This narrative review and epidemiologic commentary examines the findings and aftermath of the Women's Health Initiative (WHI) clinical trials ten years after their early termination. The author reflects on the discrepancies between pre-WHI observational epidemiologic studies and the randomized trial results evaluating oral conjugated equine estrogens (CEE) alone or CEE plus medroxyprogesterone acetate (CEE+MPA) in postmenopausal women, discussing lessons for future epidemiologic research design.
What was found
The abstract reports no numerical values, effect sizes, or confidence intervals. It states that the WHI trials demonstrated that the risks of CEE alone or CEE+MPA outweigh the benefits for the primary prevention of chronic disease in postmenopausal women, and argues that underlying data between observational studies and trials may align more closely when designs emulate randomized perspectives.
Why it matters
It emphasizes methodological insights on reconciling observational findings with randomized trials, providing a framework for evaluating preventive exposures in public health.
Limits
As a narrative review, the paper provides no systematic literature search, quantitative meta-analysis, or new primary data. Specific outcomes, risk magnitudes, and subgroup effects are not quantified in the abstract.
Cited by
- context Re-evaluation of large-scale hormone replacement therapy studies shows that HRT provides beneficial effects when initiated early in perimenopause or early menopause rather than later.